reports
- Maria Karlsson Osipova
- Maria Vara
XVIVO: solid Q4 financials bolster confidence, upgraded to BUY
XVIVO concluded 2024 with robust performance, driven by broad-based organic growth and clinical advancements. Q4 net sales reached SEK227.6m (+46% YoY, 45% in local currencies), including 44% organic growth and 1% acquired, while FY sales rose to SEK822.4m (+38% YoY, 39% in local currencies), fully
- Maria Karlsson Osipova
XVIVO Perfusion (Buy, TP: SEK566.97) - Important milestone ahead
We expect a solid end to the year, with Q4 revenue growth of 32% YOY, sales of SEK206m and EBIT of SEK25m. Following a change of analyst, we reiterate our BUY but have cut our target price to SEK567 (584) on our updated model and revised valuation approach.
- Maria Vara
XVIVO: adjusting FY2024 estimates, maintaining HOLD rating
We revisited our FY 2024 estimates following the softer traction in the abdominal segment in Q3 and slightly delayed EU heart trial launch, now awaiting CE-mark approval anticipated in Q1 2025 (instead of Q4 2024). Our revised 2024 sales estimate is SEK816m (down from SEK925.8m), while the EBITDA m
- Maria Vara
XVIVO: US heart trial enrolment completed five months ahead of schedul...
Yesterday post-market, XVIVO announced that it has completed enrolment in its US clinical trial, PRESERVE evaluating its heart preservation technology, five months ahead of schedule. Initially, enrolment was expected to take 18 months, as the trial involves 141 patients across 14 leading heart tran
- Maria Vara
XVIVO: slower abdominal and service sales, but margins overall steady
XVIVO reported Q3 2024 results, with sales coming in below expectations at SEK198.5m (vs. consensus SEK206m). The miss was largely due to slower progress in the abdominal segment, where sales increased by only 12% year-on-year but dropped 16% quarter-on-quarter. Additionally, the service segment un
- Maria Vara
XVIVO: acquisition of an innovative communication platform to save mor...
XVIVO is expanding its service offering with the acquisition of the FlowHawk software platform from OmniLife, aiming to streamline the complex planning and communication involved in organ transplantation, ensuring that "no one should die waiting for a new organ." The FlowHawk platform has proven it
- Douglas Lindahl
- Joachim Gunell
- Johan Skoglund
- Johannes Grunselius
- Jonatan Andersson
- Karl-Johan Bonnevier
- Martin Arnell
- Maria Vara
XVIVO: a scalable profitable business, yet fully valued at this level
Following the outstanding Q2 2024 earnings report on Friday, we updated our DCF model (WACC 9%, TGR 3%) (unchanged) reflecting XVIVO's improved Lung outlook, Abdominal sales to pick up from Q4 2023, as well as the positive progress on gross margin and EBITDA, which we anticipate to reach 30% in 202
- Jonatan Andersson
- Maria Vara
XVIVO: Solid sales growth, adj. EBITDA hit 24%
XVIVO reported Q2 2024 results demonstrating continued financial growth and solid clinical progress. Revenues hit over cons. at SEK 210m (BG est. of SEK SEK 205m) representing a YoY organic growth of 35% (adj. for currency), and 13% QoQ. The solid performance was driven by the thoracic business rep
- Jonatan Andersson
XVIVO Perfusion (Buy, TP: SEK520.00) - All gas no brakes heading into ...
We expect total Q2 sales growth of 31% YOY, at a 13.9% adj. EBIT margin, with solid momentum in most segments. We reiterate our BUY and have raised our target price to SEK520 (468) on 2024–2026e sales and peer-group multiple changes.
- Jonatan Andersson
XVIVO Perfusion (Buy, TP: SEK468.00) - Bullish start to the year
We have increased our 2024–2026e EBITDA by 8–15% on the strong Q1 report, with sales and EBITDA well above expectations. We reiterate our BUY and have raised our target price to SEK468 (439), due to estimate changes and peer group valuations.
- Maria Vara
XVIVO: delivering a solid Q1 2024 performance
XVIVO reported Q1 2024 results with a YoY organic growth of 32% (32% adj. for currency) in net sales raising to SEK 186m. The solid performance was driven by i) thoracic business reporting a 33% YoY growth, totalling SEK 121m sales, with disposables sales rising by 39% as of larger utilization in t
- Jonatan Andersson
XVIVO Perfusion (Buy, TP: SEK439.00) - All eyes on the heart
We expect total Q1 sales growth of 19% YOY, at a 10.7% adj. EBIT margin, with solid momentum in most segments. The company will present key data at ISHLT on its Heart Box, which we view as a share price driver. We reiterate our BUY and have raised our target price to SEK439 (418) on 2024–2026e sales and peer-group multiple changes.
- Maria Vara
XVIVO: 12h transatlantic heart preservation case ahead of EU launch mi...
Yesterday, XVIVO reported the first-ever transatlantic heart transplantation case performed, enabled by the use of XVIVO Heart Transport Assist, a non-ischemic heart preservation system. Following 12 hours of transportation, 10 hours of perfusion and 6750 km of commercial flight, the brain-dead don
- Maria Vara
- Oscar Haffen Lamm
Coverage update
Given team and strategy changes, Oscar Haffen Lamm is now assuming coverage of Medincell, Camurus, Valneva, Aelis Pharma, Abivax, Calliditas, Egetis Therapeutics, Basilea, Geneuro, Achilles, Valerio, Innate Pharma, Morphosys, Inventiva Pharma, Vicore, DBV Technologies, and Genfit.Maria Vara is now
BSLN BASILEA PHARMACEUTICA AG
IPH INNATE PHARMA SA CLASS A
VLS VALNEVA SE
ALMDT MEDIAN TECHNOLOGIES
EGTX EGETIS THERAPEUTICS AB
7CA CAMURUS AB
VICO VICORE PHARMA HOLDING AB
5142 ACHILLES CORP.
A3TV ATRESMEDIA CORPORACION DE MEDIOS DE COMUNICACION SA
XVIVO XVIVO PERFUSION AB
GNRO GENEURO SA
BONEX BONESUPPORT HOLDING AB
MOR MORPHOSYS AG
MED MEDARTIS AG
MEDCL MEDINCELL SA
CALTX CALLIDITAS THERAPEUTICS AB
IVA INVENTIVA ADS
CLNK B CELLINK AB
GNFT GENFIT
AELIS AELIS FARMA SA
ONWD ONWARD OPPORTUNITIES LIMITED
ALONX ONXEO
ABVX ABIVAX
- Johan Skoglund
- Jonatan Andersson
- Alex Cogut
- Maria Vara
2023 a year of growth
XVIVO reported FY 2023 results with sales growing by 44% resulting in net sales of SEK 598m, in line with our estimate of SEK 615m. As we acknowledge in our recent re-initiation of coverage, the Thoracic business was the major driver, however, we started to see the resurge of abdominal sales which
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.